Drug intelligence / Profile preview

Ningxin Shugan Granule

Development stage: Unknown
Lead developer: Huasen Pharmaceutical
Administration: Oral

Overview

Ningxin Shugan Granule is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Chongqing Huasen Pharmaceutical. It is approved in China for the treatment of symptoms associated with liver depression, qi stagnation, and heart-mind loss of nourishment. These symptoms commonly manifest as irritability, insomnia, dreaminess, dizziness, and emotional instability, particularly in patients with perimenopausal syndrome, depression, or anxiety. The formulation is composed of several herbal extracts, including Bupleurum chinense, Paeonia lactiflora, and Cyperus rotundus, which are traditionally used to harmonize the liver, regulate qi, and calm the spirit.

Brand names: Ningxin Shugan Granule
Other names: Ningxin Shugan Keli宁心疏肝颗粒

Beyond the preview

Go deeper on Ningxin Shugan Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ningxin Shugan Granule.

Explore the full profile